Armata Pharmaceuticals, Inc. (ARMP)
Largest Insider Buys in Sector
ARMP Stock Price History Chart
ARMP Stock Performance
About Armata Pharmaceuticals, Inc.
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.
Insider Activity of Armata Pharmaceuticals, Inc.
Over the last 12 months, insiders at Armata Pharmaceuticals, Inc. have bought $0 and sold $0 worth of Armata Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Armata Pharmaceuticals, Inc. have bought $30.38M and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 5,385,208 shares for transaction amount of $26.93M was made by Innoviva Strategic Opportunities LLC () on 2022‑03‑31.
List of Insider Buy and Sell Transactions, Armata Pharmaceuticals, Inc.
| 2022-03-31 | 5.39M 15.2956% | $5.00 | $26.93M | -26.79% | ||||
| 2022-02-09 | director | 3.61M 12.27% | $5.00 | $18.07M | -21.85% | |||
| 2021-10-29 | 1.21M 5.1858% | $3.30 | $4M | +33.75% | ||||
| 2021-03-17 | 4.29M 12.3568% | $3.25 | $13.93M | -25.41% | ||||
| 2021-01-26 | 1.87M 8.1521% | $3.25 | $6.07M | +13.46% | ||||
| 2020-03-27 | 10 percent owner | 7.72M 66.226% | $2.87 | $22.15M | +7.19% | |||
| 2018-03-22 | director | 181,820 1.2965% | $1.10 | $200,002 | -16.38% | |||
| 2018-03-22 | director | 181,820 1.2965% | $1.10 | $200,002 | -16.38% | |||
| 2017-09-19 | director | 105,015 – | $0 | $0 | +11.11% | |||
| 2017-09-19 | director | 105,015 – | $0 | $0 | +11.11% | |||
| 2017-06-29 | director | 5,757 – | $0 | $0 | +43.42% | |||
| 2017-06-29 | director | 5,757 – | $0 | $0 | +43.42% | |||
| 2016-12-29 | Sale | 10 percent owner | 42,000 0.3166% | $0.45 | $18,900 | -76.14% | ||
| 2016-12-28 | Sale | 10 percent owner | 84,620 0.6272% | $0.47 | $39,771 | -77.66% | ||
| 2016-12-27 | Sale | 10 percent owner | 50,400 0.3723% | $0.51 | $25,704 | -79.31% | ||
| 2016-11-22 | director | 46,666 4.0827% | $7.40 | $345,328 | -81.77% | |||
| 2016-06-21 | director | 15,057 – | $0 | $0 | -70.18% | |||
| 2016-04-08 | director | 171,298 – | $0 | $0 | -61.41% | |||
| 2015-10-06 | director | 10,000 0.1764% | $4.39 | $43,900 | -31.52% | |||
| 2015-10-05 | Chief Executive Officer | 4,200 0.0834% | $4.75 | $19,950 | -28.73% |
Insider Historical Profitability
| Innoviva Strategic Opportunities LLC | 16365969 45.231% | $2.04 | 1 | 0 | <0.0001% | |
| BIOGEN IDEC INC | 10 percent owner | 11704095 32.3469% | $2.04 | 1 | 23 | |
| ELAN CORP PLC | 10 percent owner | 11626282 32.1318% | $2.04 | 1 | 3 | |
| Innoviva, Inc. | director | 10980761 30.3478% | $2.04 | 5 | 0 | +1.43% |
| KIRK RANDAL J | 10 percent owner | 674169 1.8632% | $2.04 | 1 | 3 | |
| COOK JEREMY CURNOCK | director | 411105 1.1362% | $2.04 | 7 | 0 | <0.0001% |
| PERRY MICHAEL S | director | 411105 1.1362% | $2.04 | 3 | 0 | <0.0001% |
| PARKER H STEWART | President & CEO | 31175 0.0862% | $2.04 | 1 | 0 | |
| DRAPEAU LOUIS | director | 10000 0.0276% | $2.04 | 1 | 0 | |
| Salka Michael Scott | Chief Executive Officer | 4200 0.0116% | $2.04 | 1 | 0 | |
| Johnson Wendy S. | Interim Chief Operating Office | 1000 0.0028% | $2.04 | 1 | 0 | |
| MARXE AUSTIN W & GREENHOUSE DAVID M | 10 percent owner | 0 0% | $2.04 | 0 | 15 |
Institutional Investor Ownership
| Bank of America | $2.66M | 1.76 | 636,638 | +0.34% | +$9,141.66 | <0.0001 | |
| The Vanguard Group | $665,494.00 | 0.44 | 159,209 | +9.74% | +$59,067.61 | <0.0001 | |
| Bridgeway Capital Management | $461,397.00 | 0.31 | 110,382 | 0% | +$0 | 0.01 | |
| Edgewood Management | $418,000.00 | 0.28 | 100,000 | 0% | +$0 | <0.01 | |
| Geode Capital Management | $417,648.00 | 0.28 | 99,888 | -1.11% | -$4,703.81 | <0.0001 | |
| Susquehanna International Group | $367,017.00 | 0.24 | 87,803 | New | +$367,017.00 | <0.0001 | |
| Renaissance Technologies | $215,000.00 | 0.14 | 51,396 | -4.11% | -$9,203.05 | <0.0001 | |
| State Street | $168,454.00 | 0.11 | 40,300 | 0% | +$0 | <0.0001 | |
| SeaCrest Investment Management, LLC | $137,008.00 | 0.09 | 32,777 | +80.79% | +$61,224.52 | 0.02 | |
| BlackRock | $99,768.00 | 0.07 | 23,868 | +4.87% | +$4,631.43 | <0.0001 | |
| Qube Research & Technologies | $93,691.00 | 0.06 | 22,414 | -4.88% | -$4,802.85 | <0.0001 | |
| Northern Trust | $80,641.00 | 0.05 | 19,292 | -0.45% | -$367.84 | <0.0001 | |
| Citadel Advisors LLC | $75,094.00 | 0.05 | 17,965 | New | +$75,094.00 | <0.0001 | |
| CAPTRUST | $54,925.00 | 0.04 | 13,140 | -3.01% | -$1,705.43 | <0.0001 | |
| Tower Research Capital | $7,093.00 | 0.01 | 1,697 | -49.6% | -$6,980.15 | <0.0001 | |
| Trifecta Capital Advisors Llc | $2,985.00 | <0.01 | 714 | 0% | +$0 | <0.01 | |
| UBS | $3,206.00 | <0.01 | 767 | +76,600% | +$3,201.82 | <0.0001 | |
| Northwestern Mutual Wealth Management Co | $2,387.00 | <0.01 | 571 | 0% | +$0 | <0.0001 | |
| Morgan Stanley | $1,780.00 | <0.01 | 426 | +21,200% | +$1,771.64 | <0.0001 | |
| JPMorgan Chase | $109.00 | <0.01 | 26 | -75.24% | -$331.19 | <0.0001 | |
| Wells Fargo | $357.00 | <0.01 | 86 | +2.38% | +$8.30 | <0.0001 | |
| Householder Group Estate Retirement Specialist Llc | $568.00 | <0.01 | 136 | 0% | +$0 | <0.0001 | |
| Salem Investment Counselors | $418.00 | <0.01 | 100 | 0% | +$0 | <0.0001 | |
| Royal Bank of Canada | $0 | <0.01 | 26 | -90.78% | -$0 | <0.0001 |